UPDATE: JPMorgan Starts IDEXX Laboratories (IDXX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
UPDATE: IDEXX Labs (IDXX) Tops Q4 EPS by 62c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus
February 2, 2021 6:35 AM EST(Updated - February 2, 2021 7:01 AM EST)
IDEXX Labs (NASDAQ: IDXX) reported Q4 EPS of $2.01, $0.62 better than the analyst estimate of $1.39. Revenue for the quarter came in at $720.94 million versus the consensus estimate of $680.03 million.
Achieves fourth quarter reported revenue growth of 19% and organic growth of 17%, driven by CAG Diagnostics recurring revenue reported growth of 23% and organic growth of 21%High revenue growth supported by sustained strong global trends in pet healthcareDelivers full year... More